|
| 抗EGFR再挑战在转移性结直肠癌三线治疗中的应用进展 |
| Research Progress on Anti-EGFR Rechallenge for The Third-Line Therapy of Metastatic Colorectal Cancer |
| 投稿时间：2024-06-04 修订日期：2024-07-29 |
| DOI： |
|
 |
| 中文关键词: 抗EGFR再挑战 RAS野生型 转移性结直肠癌 |
| 英文关键词:anti- EGFR rechallenge RAS wild-type metastatic colorectal cancer |
| 基金项目: |
|
| 摘要点击次数: 108 |
| 全文下载次数: 0 |
| 中文摘要: |
| 表皮生长因子受体（Epidermal Growth Factor Receptor, EGFR）单克隆抗体是治疗转移性结直肠癌患者的有效一线药物。然而，抗EGFR治疗后获得性耐药的出现限制了EGFR抑制剂在转移性结直肠癌持续治疗中的应用。基于分子生物学的研究，抗EGFR再挑战策略在RAS/BRAF野生型转移性结直肠癌患者二线治疗后的临床管理中具有潜在活性。本文综述了抗EGFR再挑战策略在转移性结直肠癌三线治疗中的疗效及其相关毒性，并探讨了疗效预测因素的研究进展，为临床实践和科学研究提供新的视角。 |
| 英文摘要: |
| The epidermal growth factor receptor (EGFR) monoclonal antibody is an effective first-line drug for metastatic colorectal cancer patients. However, the emergence of acquired resistance after anti-EGFR therapy limits the use of EGFR inhibitors in the sustained treatment of metastatic colorectal cancer. Based on molecular biology research, the anti-EGFR rechallenge strategy has potential activity in clinical management of RAS/BRAF wild-type metastatic colorectal cancer patients after second-line treatment. This article reviews the efficacy and related toxicity of the anti-EGFR rechallenge strategy in the third-line treatment of metastatic colorectal cancer, and explores the research progress of efficacy prediction factors, providing a new perspective for clinical practice and scientific research. |
|
在线阅读
查看/发表评论 下载PDF阅读器 |